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Abstract
Objective
To investigate and compare occult damages in aquaporin-4 (AQP4)-rich periependymal
regions in patients with neuromyelitis optica spectrum disorder (NMOSD) vs healthy controls
(HCs) and patients with multiple sclerosis (MS) applying quantitative T1 mapping at 7
Tesla (T) in a cross-sectional study.
Methods
Eleven patients with NMOSD (median Expanded Disability Status Scale [EDSS] score 3.5,
disease duration 9.3 years, age 43.7 years, and 11 female) seropositive for anti-AQP4 antibodies,
7 patients with MS (median EDSS score 1.5, disease duration 3.6, age 30.2 years, and 4 female),
and 10 HCs underwent 7T MRI. The imaging protocol included T2*-weighted (w) imaging
and an MP2RAGE sequence yielding 3D T1w images and quantitative T1 maps. We semi-
automatically marked the lesion-free periependymal area around the cerebral aqueduct and the
lateral, third, and fourth ventricles to finally measure and compare the T1 relaxation time within
these areas.
Results
We did not observe any differences in the T1 relaxation time between patients with NMOSD
and HCs (all p > 0.05). Contrarily, the T1 relaxation time was longer in patients with MS vs
patients with NMOSD (lateral ventricle p = 0.056, third ventricle p = 0.173, fourth ventricle p =
0.016, and cerebral aqueduct p = 0.048) and vs HCs (third ventricle p = 0.027, fourth ventricle p
= 0.013, lateral ventricle p = 0.043, and cerebral aqueduct p = 0.005).
Conclusion
Unlike in MS, we did not observe subtle T1 changes in lesion-free periependymal regions in
NMOSD, which supports the hypothesis of a rather focal than diffuse brain pathology in
NMOSD.
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Neuromyelitis optica spectrum disorder (NMOSD) is a severe
and often devastating autoimmune and inflammatory CNS
disease frequently associated with autoantibodies targeting
aquaporin-4 (AQP4) water channels leading to complement
activation and focal lesions within AQP4-rich CNS areas such as
the spinal cord, the optic nerves, and periependymal regions.1,2 In
more detail, brain AQP4 water channels are predominantly lo-
cated within astrocyte foot processes in the glial limiting mem-
brane and in the basolateral cell plasma membrane of ependymal
cells.3,4
Clinical,5 MRI,6 and optical coherence tomography findings
mirror the anatomic distribution of AQP4 water channels
within the CNS.7–9 MRI is used to rule out other disorders
and to visualize optic neuritis and signs of myelitis.6 On top of
that, brain lesion patterns typical for NMOSD have been
described including extensive or tumefactive periventricular
lesions around the lateral, third, and fourth ventricles and the
cerebral aqueduct affecting, e.g., diencephalic structures, the
area postrema, the thalamus, the hypothalamus, the corpus
callosum, or the periventricular white matter.6 Nevertheless,
NMOSD-specific brain MRI abnormalities are only detect-
able within a small proportion of patients,10 and many
patients with NMOSD present with a normal brain MRI,11
which in the past has led to the inclusion of “negative brain
MRI at onset” to the 2006 Wingerchuk diagnostic criteria.12
Quantitative MRI allows for the quantification of physical
variables such as the T1 relaxation time that is sensitive to free-
water protons and structural damage to finally compare those
variables between tissue regions or participants. When com-
bining quantitative MR techniques with ultra-high-field MRI at
7 Tesla that benefits from an increased signal-to-noise ratio,
even subtle degenerative or inflammatory changes that are not
obviously present on standard MR images can be assessed.13,14
On this background, we here prospectively performed quan-
titative T1 relaxometry at 7T to search for occult brain
damage within the AQP4-rich, lesion-free and normal-
appearing periependymal white or gray matter of patients
with NMOSD.We compared our results with those in healthy
controls (HCs) and patients with multiple sclerosis (MS).
Methods
Participants
Eleven patients with NMOSD as defined by the 2015 in-
ternational consensus diagnostic criteria1 were
prospectively recruited from the outpatient clinic of the
department of neurology, Charite´—Universita¨tsmedizin
Berlin between January 2014 and December 2015. For
comparison, 10 age-matched HCs and 7 patients with
relapsing-remitting MS (RRMS), which were best com-
parable regarding age and sex, were selected from the
NeuroCure neuroimaging database as controls. AQP4
antibody serostatus was assessed in patients with NMOSD
using one of several established assays.15–17 Antibodies
against AQP4 were present in all patients with NMOSD.
Clinical disability was assessed using the Expanded Dis-
ability Status Scale (EDSS) in patients with MS and
NMOSD.
Standard protocol approvals, registrations,
and patient consents
The Ethics Committee of the Charite´–Universita¨tsmedizin
Berlin in conformity with the Declaration of Helsinki ap-
proved the study (EA 1/054/09). All participants provided
written informed consent.
MRI acquisition
Ultra-high-field MR images were acquired using a 7T Sie-
mens whole-body scanner (Magnetom; Siemens, Erlangen,
Germany) and a 24-channel receive head coil (Nova Medi-
cal, Wilmington, MA) equipped with a birdcage volume coil
for transmission. The imaging protocol included
2-dimensional T2*-weighted fast low angle shot (T2*w
FLASH; echo time [TE] = 25.0ms, repetition time [TR] =
1,820 ms; spatial resolution = [0.5 × 0.5 × 2] mm3, supra-
tentorial coverage) and 3-dimensional fluid-attenuated in-
version recovery (FLAIR, TE = 90 ms; TR = 16,000 ms;
inversion time [TI] = 2,925 ms, spatial resolution = [1.0 ×
1.0 × 3.0] mm3).
A 3-dimensional T1-weighted magnetization-prepared
rapid gradient-echo sequence with 2 TIs (T1w
MP2RAGE, TE = 2.98 ms; TR = 2,300 ms; TI = 900 ms;
spatial resolution = (1.0 × 1.0 × 1.0) mm3, whole-brain
coverage) was used to generate bias-field corrected T1w
images and quantitative T1 maps. Phantom experiments
have shown that T1 relaxation times measured using the
MP2RAGE approach are closely correlated in a linear
fashion with true T1 physical values commonly observed
within the brain.18
Image analysis
All images were analyzed and processed using 3D Slicer
(Version 4.6.2 on MacOS 10.11.4, The Slicer Community),
Glossary
AQP4 = aquaporin-4; DTI = diffusion tensor imaging; EDSS = Expanded Disability Status Scale; FLAIR = fluid-attenuated
inversion recovery;HC = healthy control;MRS =MR spectroscopy;NAA =N-acetylaspartic acid;NAWM = normal-appearing
white matter; NMOSD = neuromyelitis optica spectrum disorder; RRMS = relapsing-remitting multiple sclerosis; TE = echo
time; TI = inversion time; TR = repetition time.
2 Neurology: Neuroimmunology & Neuroinflammation | Volume 6, Number 3 | March 2019 Neurology.org/NN
and fslmaths integrated in the FMRIB Software Library
(FSL, version 5.0, FMRIB, Oxford, United Kingdom).
To semiautomatically segment periependymal regions, we
defined regions of interest (table 1) and applied a 5-step
procedure (figure 1).
First, the lateral, third, and fourth ventricles and the cerebral
aqueducts were segmented in consensus reading by a trained
and blinded investigator (B.P.) using a semiautomatic
threshold-based approach with best visual correction on T1w
images. Next, the border of all regions of interest was auto-
matically dilated by 1 mm to avoid partial volume effects of
Table 1 Anatomic boundaries for segmentation
Name of
the mask
Anatomic boundaries of the mask
Structures within the
maskAnterior Posterior Superior Inferior Medial
Lateral
ventricle
Anterior horn Posterior horn Body of the lateral
ventricle
End of the anterior
horn
Septum
pellucidum
Audate nucleus, Genu of
corpus callosum
Corpus callosum End of the posterior
horn
Interventricular
foramen
Splenium of corpus
callosum
Inferior horn until
collateral trigone
Forceps minor
Tapetum
Inferior fronto-occipital
fasciculus
Optic radiation
Third
ventricle
Lamina terminalis Quadrigeminal
cistern
Beginning of the
third ventricle
Cerebral aqueduct Interthalamic
adhesion
Thalamus
Cistern of the
lamina terminalis
Posterior
commissure
Anterior commissure
Interventricular
foramina
Pineal gland Posterior commissure
Fornix
Fourth
ventricle
Rhomboid fossa Cerebellum Superior medullary
velum
Inferior cerebellar Nodulus Medial longitudinal
fasciculus
Bottom of the
fourth ventricle
Fastigium Peduncle Superior cerebellar
peduncle
Cerebral
aqueduct
Opening of the
cerebral aqueduct
Entry in the fourth
ventricle
Periaqueductal gray
matter
Inferior colliculus
The table provides an overview on the anatomic boundaries that were used for segmentation of the ventricles.
Figure 1 Segmentation of the normal-appearing periependymal white matter
The figure demonstrates the procedure to segment the normal-appearing periependymal white matter. First, the ventricles were segmented (A) and dilated
by 1 mm to avoid partial volume effects and 2 mm to include the periependymal white matter (B). Second, the 1-mm dilated ventricle mask was subtracted
from the 1 + 2mmdilated ventriclemask (C). Finally, the periependymalmaskwasmanually edited for smaller errors, and the lesionmask was subtracted (D)
to overlay the final mask with T1 maps (E).
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the CSF on the final analysis. Third, the border of all regions
of interest was automatically dilated by 2 mm, and the 1-mm
dilated mask was then subtracted from the 3-mm dilated
mask. This step hence creates a 2-mm-thick small rim around
the ventricles, which represents the periependymal white
matter. Fourth, T1 hypointense and FLAIR/T2*w hyperin-
tense white matter lesions were manually segmented to sub-
tract the lesion map from previously created region-specific
periependymal masks. Finally, periependymal masks of the
lateral ventricles were split into white and (cortical and deep)
gray matter areas by applying T1-threshold-based approach
with best visual correction.
The region-specific, CSF-free, lesion-free, and 2-mm-thick
periependymal region masks were then used to calculate the
mean T1 relaxation time per region and participant using
the Label Statistics Module integrated in 3D Slicer
(figure 2).
In addition, the lesion count was assessed on T2*w images.
Hereby, all T2*w hyperintense lesions larger than 2 mm were
counted.
Statistical analysis
All analyses were performed using IBM SPSS Statistics (ver-
sion 20, IBM, Somers, NY). Normal distribution was assessed
visually and by using a Shapiro-Wilk test. T1 measures around
the third ventricle, the fourth ventricle, the cerebral aqueduct,
and the lateral ventricle (gray matter) were normally dis-
tributed. Thus, the Student t test was used to assess group
differences in mean T1 between patients with NMOSD, MS,
and HCs. T1 measures around the lateral ventricle were not
normally distributed. Thus, Mann-WhitneyU test was used to
assess group differences in mean T1 (lateral ventricle) between
patients with NMOSD, MS, and HCs. Sex differences were
assessed using the chi-squared test, and differences in age were
assessed using the Student t test. p-Values <0.05 were considered
statistically significant. Given the exploratory nature of the study,
no adjustments for multiple comparisons were made.
Data availability
This study was supported by a grant from the Guthy-Jackson
Charitable Foundation, which supports the idea of data sharing
to facilitate research in the field of NMOSD. Hence, deidentified
7TMRI data of patients withNMOSD included in this studywill
be shared by the corresponding author with qualified scientific
collaborators for research projects on request.
Results
Cohort description
Eleven AQP4 antibody–positive patients with NMOSD
and a mean ± SD age of 43.7 ± 7.12 years (range 22–69
years) were included. Ten HCs (mean ± SD age 41.6 ± 11.8
years, range 29–67 years) and 7 patients with RRMS (mean
± SD age 30.2 ± 7.9 years, range 21.4 years) served as
controls.
Patients with NMOSD had a total number of 154 (mean ± SD
14 ± 16.5, range 0–55) lesions. A total number of 143 lesions
(mean ± SD 20.4 ± 17.4, range 0–53) were detectable in
patients with MS. More clinical details including the EDSS
score and sex are presented in table 2.
T1 relaxation time of periependymal regions in
healthy controls
Table 3 gives an overview of all results. The mean T1 relaxation
time of periependymal regions around the lateral ventricle in
HCs was 1,355.6 ± 49.3 ms (range 1,296.5–1,472.4 ms). Gray
matter areas had a mean T1 relaxation time of 1772.9 ± 23.1 ms
(range 1741.9–1819.5 ms), whereas white matter areas had
a mean T1 relaxation time of 1,220.9 ± 53.8 ms (range
1,166.8–1,358.6 ms).
Furthermore, we observed a mean T1 relaxation time of
1,534.7 ± 47.5 ms (range 1,470.0–1,597.1 ms) of periependymal
regions around the third ventricle, a mean T1 relaxation time of
1,359.2 ± 25.5 ms (range 1,322.9–1,409.9 ms) of periependymal
regions around the fourth ventricle, and a mean T1 relaxation
Figure 2 Exemplary masks of periependymal regions
The figure demonstrates exemplary masks of segmented periependymal regions around the third ventricle (A), the lateral ventricles (B), the cerebral
aqueduct (C), and the fourth ventricle (D).
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time of 1,671.0 ± 49.3 ms (range 1,609.5–1753.5 ms) of peri-
ependymal regions around the cerebral aqueduct.
T1 relaxation time of periependymal regions in
patients with NMOSD
Table 3 and figure 3 give an overview of all results. In com-
parison to HCs, we observed comparable mean T1 relaxation
time of periependymal regions around the lateral (p = 0.557),
third (p = 0.773), and fourth ventricles (p = 0.372), as well as
around the cerebral aqueduct (p = 0.754).
T1 relaxation time of periependymal regions in
patients with MS
Table 3 and figure 3 give an overview of all results. In com-
parison to HCs, we observed longer T1 relaxation times of
periependymal regions around the lateral (p = 0.043), third
(p = 0.027), and fourth ventricles (p = 0.013), as well as
around the cerebral aqueduct (p = 0.005).
In comparison to NMOSD, we observed longer T1 relaxation
times of periependymal regions around the lateral (p = 0.056),
third (p = 0.173), and fourth ventricles (p = 0.016), as well as
around the cerebral aqueduct (p = 0.048).
Discussion
In this study, we aimed to explore occult brain damage in
normal-appearing periependymal regions that are character-
ized by a high expression of AQP4 water channels in patients
with AQP4 antibody–positive NMOSD by quantitative MRI
with a high signal-to-noise ratio at 7 Tesla. We found that T1
Table 2 Cohort overview
HC NMOSD RRMS
n (n, female, p value) 10 (9) 11 (11), p = 0.28 7 (4), p = 0.12
age (years, mean ± SD, range, p value) 41.6 ± 11.8, 29–67 43.7 ± 14.2, 22–69, p = 0.71 30.2 ± 7.9, 21–40, p = 0.04
Disease duration
(y, mean ± SD, range)
NA 9.3 ± 8.1, 1–29 3.6 ± 2.1, 0.3–6.6
EDSS (median, range) NA 3.5, 1.5–5.0 1.5, 0–3.0
Abbreviations: NMOSD = neuromyelitis optica spectrum disorder; RRMS = relapsing-remitting MS; HC = healthy control; EDSS = Expanded Disability Status
Scale; NA = not applicable.
Clinical details on studied participants are displayed.
p Values describe differences between NMOSD and RRMS vs HCs.
Table 3 T1 of periependymal regions in patients with NMOSD or RRMS and HCs
HC NMOSD MS
Lateral ventricle (T1 in ms, mean ± SD, range, p
value)
1,355.6 ± 49.3;
1,296.5–1,472.4
1,354.4 ± 82.1; 1,269.7–1,568.5;
p = 0.557
1,405.6 ± 61.9;
1,331.3–1,508.9;
p = 0.043
Lateral ventricle GM (T1 inms, mean ± SD, range, p
value)
1772.9 ± 23.1;
1741.9–1819.5
1769.5 ± 45.3; 1,679.9–1831.1;
p = 0.838
1816.5 ± 34.4;
1776.8–1877.6;
p = 0.007
Lateral ventricleWM (T1 inms,mean ± SD, range, p
value)
1,220.9 ± 53.8;
1,166.8–1,358.6
1,224.8 ± 77.6; 1,162.9–1,441.1;
p = 0.809
1,261.5 ± 64.6;
1,210.0–1,393.4;
p = 0.070
Third ventricle (T1 inms,mean± SD, range,p value) 1,534.7 ± 47.5;
1,470.0–1,597.1
1,545.1 ± 103.8; 1,414.56–1773.81;
p = 0.773
1,606.8 ± 58.4;
1,534–1711.2;
p = 0.027
Fourth ventricle (T1 in ms, mean ± SD, range, p
value)
1,359.2 ± 25.5;
1,322.9–1,409.9
1,345.6 ± 40.3; 1,292.2–1,423.6;
p = 0.372
1,397.0 ± 38.2;
1,353.3–1,450.3;
p = 0.013
Cerebral aqueduct (T1 in ms, mean ± SD, range, p
value)
1,671.0 ± 49.32;
1,609.5–1753.5
1,680.5 ± 82.45; 1,544.8–1830.1; p =
0.754
1757.1 ± 57.1;
1,698.1–1846.3;
p = 0.005
Abbreviations: NMOSD=neuromyelitis optica spectrumdisorder; RRMS= relapsing-remittingMS;HC=healthy control; GM=graymatter;WM=whitematter.
T1 relaxation times of periependymal regions in patients with NMOSD or RRMS and HCs are displayed. p Values describe differences between NMOSD and
RRMS vs HCs. p values <0.05 are highlighted in bold.
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relaxation times in normal-appearing periependymal regions
did not differ between patients with NMOSD and HCs.
The T1 relaxation time is predominantly influenced by
structural changes or damage and free protons found in, e.g.,
inflammatory edema.19 In other words, both structural damage
and edema lead to a prolongedT1 in comparison to healthy brain
tissue. By applying quantitative T1 relaxometry at 7 Tesla, one
benefits from a substantially increased signal-to-noise ratio and
hence increased sensitivity for changes in T1. Thus, T1 relaxation
times within the range of those found in HCs argue against the
existence of structural damage or edema within the analyzed
periependymal regions in patients with AQP4 antibody–positive
NMOSD.
Indeed, most previousMRI studies have described no or more
focal lesions within the NMOSD brain.6,8,9,20 Although
NMOSD-specific lesions are often found in AQP4-rich peri-
ependymal regions of diencephalic structures, the area post-
rema, the thalamus, the hypothalamus, the corpus callosum,
or the periventricular white matter,6 there is only little evi-
dence on a more diffuse or occult damage in those regions.21
Several studies have investigated a diffuse or occult damage
within the normal-appearing white matter (NAWM) of patients
with NMOSD by applying different MRI techniques.
Proton MR spectroscopy (MRS) is a widely applied method
used to assess metabolic alterations and the integrity of axonal
and neuronal structures. In NMOSD, normal N-acetylaspartic
acid (NAA), creatine, and choline levels were reported within
the NAWM, arguing against occult axonal or neuronal dam-
age, inflammation, and gliosis.22–24 A recent well-powered
MRS study confirmed these findings by reporting normal
NAA levels in NMOSD.25
Furthermore, diffusion tensor imaging (DTI)—that is sensi-
tive to structural changes—has been performed in NMOSD.
DTI data on the NAWM inNMOSD are inconclusive. On the
one hand, no DTI abnormalities were reported within brain
regions,26 except for the visual pathway where Wallerian de-
generation may occur after optic neuritis.27,28 Contrarily,
other research groups have observed fractional anisotropy
changes—a marker of the structural integrity—within the
NAWM of patients with NMOSD.29,30 Such DTI abnor-
malities were, however, rather mild and not as severe as in
patients with MS.31
Another technique to analyze a more global brain pathology is
structural volumetric imaging. Although some groups repor-
ted no26 or only mild brain volume changes in NMOSD,32,33
others observed white matter volume loss34 but not cortical gray
matter volume loss, which contrast atrophy measures in MS.35
Finally, a 7TMRI study on the periventricular venous density
in patients with NMOSD did not report changes in venous
visibility on highly resolving T2*w images arguing against
a widespread hypometabolism in NMOSD.36
Figure 3 Box plots
Box plots ofmean T1 valueswithin periependymal regions around the lateral ventricles, the third ventricle, the cerebral aqueduct, and the fourth ventricle are
displayed.
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All these studies indicate that occult or diffuse brain damage
either is absent or only plays a minor role in the pathophys-
iology of NMOSD,21–31 whichmay result in less brain atrophy
in comparison to MS.26,32–35 Of note, this assumption is well
in line with the clinical presentation of NMOSD.2,5 The latter
is often characterized by a relapsing-remitting or monophasic
disease course. A (secondary) progressive disease course is
rare in NMOSD.2,5
In contrast to NMOSD, we clearly observed prolonged T1
relaxation times in patients with MS, especially within the
periependymal thalamus and caudate nuclei. Those results
may either reflect diffuse normal-appearing white and gray
matter damage in MS as indicated by MRS,25 DTI,31 volu-
metric37 or quantitative T1 studies,38 or is caused by small
lesions within, e.g., the thalamus that are not obviously seen
on conventional MRI.39
Our study is not free of limitations. Although all lesion
masks and periependymal regions of interest (ROIs) were
best visually corrected with high diligence, we cannot ex-
clude minor misclassifications and partial volume effects.
Periependymal ROIs were, however, created with a 1-mm
“security” distance around the ventricles. Thus, partial
volume effects should not have a relevant effect on this
work. In addition, the number of analyzed patients with MS
was relatively low.
Our findings of normal T1 relaxation times in normal-
appearing lesion-free periependymal regions of patients with
NMOSD argue against a severe diffuse or occult brain damage
even in AQP4-rich brain regions, which is well in line with the
literature, the clinical phenotype of NMOSD, and in contrast
to MS. Future work needs to ask, what pathophysiologic
processes exactly drive lesion formation in AQP4 antibody–
positive human NMOSD.40
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